[Photochemotherapy of cutaneous lymphoma: oral and local 8-MOP-UVA treatment (author's transl)].
8-Methoxypsoralen (8-MOP) and long-wave ultra-violet light (UVA) were administered to 16 patients with mycosis fungoides and to three with other cutaneous lymphomas. Total body clearing was achieved in eleven patients, while temporary recurrences were observed in three, maintenance treatment arresting the recurrences. In the others all treatment failed. Histological and enzyme-cytochemical studies indicate that the histological features under 8-MOP-UVA treatment correspond to those induced by other forms of treatment: a lose enzyme-cytochemically negative lymphocytoid infiltrate remaining around blood vessels, after regression of the skin disease. Oral 8-MOV-UVA treatment (12 patients) proved superior to topical treatment (seven patients), because cutaneous lymphoma is a systemic disease. In mycosis fungoides the mean number of exposures causing clearance of skin lesions and the mean UVA dose (single treatment) were generally less than those for psoriasis vulgaris.
D000368:Aged; D003873:Dermatitis, Exfoliative / Q000188:drug therapy / Q000532:radiotherapy; D005260:Female; D006801:Humans; D007645:Keratoderma, Palmoplantar / Q000188:drug therapy / Q000532:radiotherapy; D008206:Lymphatic Diseases / Q000188:drug therapy / Q000532:radiotherapy; D008223:Lymphoma / Q000628:therapy*; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy / Q000532:radiotherapy; D008297:Male; D008730:Methoxsalen / Q000627:therapeutic use; D008875:Middle Aged; D009182:Mycosis Fungoides / Q000188:drug therapy / Q000532:radiotherapy / Q000628:therapy*; D012878:Skin Neoplasms / Q000188:drug therapy / Q000532:radiotherapy / Q000628:therapy*; D013577:Syndrome; D014467:Ultraviolet Therapy
D008730:Methoxsalen
Photochemotherapie kutaner Lymphome. Orale und lokale 8-MOP-UVA-Therapie.